Drug-Drug Interactions in HIV/HCV Coinfection

Experts discuss the management of drug-drug interactions in patients receiving treatment for HIV and HCV coinfection.

HCV Racial Disparities and Treatment Outcomes

Racial disparities in HCV treatment outcomes can be partially explained by the differences in underlying immune/genetic characteristics of patients.

Preventing HCV With Needle/Syringe Programs

Needle/syringe programs (NSPs) have proven to be effective and moderately effective in preventing transmission of HCV infection and minimizing drug-related harms among people who inject ...

Short-Duration Treatment Regimens for HCV

The high cost of DAA-based regimens remains an ethical issue and an obstacle to treatment accessibility. Shorter treatment regimens may offer substantial cost savings, improved ...

Treatment Challenges for Genotype 3 HCV

Data have shown patients with genotype 3 HCV have faster progression of fibrosis and higher rates of cirrhosis, severe steatosis, and hepatocellular carcinoma.

Hepatocellular Carcinoma: Treatment Challenges

Despite continual efforts aimed at finding new treatment options, HCC still has a very low 5-year survival rate, less than 20%, as many patients are ...

Hepatitis B: Current State of Affairs

One of the main challenges in managing and controlling hepatitis B infection today is identifying people who are infected and ensuring that they have access ...

Latest News

Good Outcomes for HCV-Negative Recipients of HCV Kidneys

Good Outcomes for HCV-Negative Recipients of HCV Kidneys

Hepatitis C virus-negative recipients of HCV-infected kidneys experience HCV cure and good quality of life.

Mulpleta Approved for Thrombocytopenia in Patients With Chronic Liver Disease

Mulpleta Approved for Thrombocytopenia in Patients With Chronic Liver Disease

The FDA has approved Mulpleta for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

Hep B Core Antibody-Positive Organs May Provide Solutions to the Organ Donor Crisis

Hep B Core Antibody-Positive Organs May Provide Solutions to the Organ Donor Crisis

Hepatitis B core Antibody (anti-HB c+) organs may be a safe and ethical transplant option in an era where increased medical knowledge has enabled greater treatment for hepatitis.

WHO Targets for Chronic Hepatitis B Will Be Cost-Effective

WHO Targets for Chronic Hepatitis B Will Be Cost-Effective

Meeting World Health Organization targets for chronic hepatitis B by 2030 will be cost-effective.

NFID Initiative Working to Up Hepatitis B Vaccination Rates

NFID Initiative Working to Up Hepatitis B Vaccination Rates

A new initiative to increase hepatitis B virus vaccination rates among at-risk adults has been developed.

Canada Updates Guidelines for Hepatitis C Virus Infection

Canada Updates Guidelines for Hepatitis C Virus Infection

The Canadian Medical Association provided an updated evidence-based recommendations for the treatment of patients with chronic hepatitis C virus.

Novel Hepatitis B Virus Treatment Gets FDA's Fast Track Designation

Novel Hepatitis B Virus Treatment Gets FDA's Fast Track Designation

The FDA has granted Fast Track designation to a novel antiviral in development for the treatment of HBV infection.

Blood-Brain Barrier Damage, Psychiatric Impairment in HCV Infection and Alcohol Abuse

Blood-Brain Barrier Damage, Psychiatric Impairment in HCV Infection and Alcohol Abuse

Alcohol use disorder in patients with HCV infection is associated with increased symptoms of depression and anxiety compared with patients with HCV and no history of alcohol abuse.

Universal Screening Best Strategy for Hepatitis C in France

Universal Screening Best Strategy for Hepatitis C in France

Universal screening is the most effective strategy for hepatitis C virus in France.

Keytruda sBLA Granted Priority Review for Advanced Hepatocellular Carcinoma

Keytruda sBLA Granted Priority Review for Advanced Hepatocellular Carcinoma

The sBLA is based on results from the Phase 2 KEYNOTE-224 trial, which enrolled 104 individuals with advanced hepatocellular carcinoma previously treated with sorafenib who were either intolerant to or showed progression of disease after treatment.

Sign Up for Free e-newsletters